McKesson -- 8.2/10 -- $883.34

McKesson is the #1 US pharmaceutical distributor with approximately 41% market share, operating within a textbook oligopoly alongside Cencora (~35%) and Cardinal Health (~22%) that collectively controls over 90% of the market. Barriers to entry are immense: regulatory requirements, massive scale, deep customer relationships, and capital intensity have prevented any new entrant from emerging in decades. The business is a high-volume, low-margin toll road -- gross margins run ~3.5%, but the sheer volume (record quarterly revenue of $106.2B in FY26Q3) generates substantial gross profit dollars and cash flow.

Growth is firing on multiple cylinders. GLP-1 distribution revenue hit $14B in Q3 FY2026 (+26% YoY), with MCK serving as the primary distribution backbone for Novo Nordisk and Eli Lilly. The Oncology and Multispecialty segment is the fastest-growing at 37% YoY (24% organic), anchored by the US Oncology Network (~3,400 providers) and expanding via acquisitions into ophthalmology and retina care. Prescription Technology Solutions is delivering margin expansion through AI and automation (18% operating profit growth on 9% revenue growth). The planned Med-Surg IPO in H2 CY2027 is a catalyst to unlock value and simplify the equity story.

Management has built an exceptional track record of execution. Brian Tyler (CEO since 2019) and Britt Vitalone (CFO since 2018) have raised EPS guidance every quarter for three consecutive fiscal years -- the hallmark of an under-promise, over-deliver culture. The 5-year adjusted EPS CAGR is 18%, ROIC exceeds 30% (up >1,900 bps since FY2020), and the company consistently repurchases ~$2B in shares annually, reducing the share count 3-4% per year.

MCK receives a composite score of 8.2/10, reflecting a high-quality compounding machine in a textbook oligopoly with multiple secular growth vectors.

Bull case: McKesson is the dominant player in US pharma distribution with ~41% share in a market where the Big 3 control >90%. Growth is multi-dimensional: GLP-1 distribution ($14B/quarter, +26% YoY) provides a secular tailwind with years of runway as obesity and diabetes treatments expand globally. The Oncology platform is scaling rapidly (37% segment growth, 51-55% guided OP growth) and expanding into adjacent specialties. AI and automation are delivering measurable operating leverage (138bp opex improvement, 120 more patients per FTE). The Med-Surg IPO in H2 CY2027 is a clear catalyst to unlock value. Management has raised EPS guidance every quarter for three consecutive fiscal years, delivering an 18% 5-year EPS CAGR. On FY2027E EPS of ~$44, the forward P/E compresses to ~20x.

Bear case: At ~22-27x earnings, MCK trades at a significant premium to historical distribution multiples. The stock needs to sustain 15%+ EPS growth to justify the premium, and any miss could trigger meaningful multiple compression. Drug pricing reform (IRA, MFN, Globe) creates periodic policy overhang. GLP-1 concentration risk is real at $14B/quarter. Gross margin % continues to compress from high-volume, low-margin pass-through revenue, even as gross profit dollars grow.

Key differentiator vs. oligopoly peers (COR, CAH): MCK has the broadest platform (distribution + oncology + biopharma services), the strongest growth profile, and the most active portfolio management (European exit complete, Med-Surg IPO on track). It deserves the premium multiple.

Key catalysts and monitoring points:

• FY2026 Q4 earnings and FY2027 guidance (May 2026): Given the pattern of conservative initial guidance followed by quarterly raises, the FY2027 initial guide will set the tone. Street expects ~$44 adj EPS. Watch whether management maintains the raise-every-quarter cadence.
• GLP-1 distribution trajectory: $14B/quarter and growing 26% YoY. Track cold chain capacity expansion (50% refrigeration increase underway) and any supply disruption or biosimilar competitive dynamics.
• Oncology organic growth vs. acquisition noise: The 37% headline segment growth includes acquisitions (FL Cancer Specialists, Prism Vision). Organic growth of ~24% and 15% organic OP growth are the more important signals to track.
• Med-Surg IPO progress (H2 CY2027): TSAs in place since Jan 2026. Watch for S-1 filing, market conditions, and any delays. This is a meaningful value-unlock catalyst.
• AI/automation margin expansion: Management cites 120 more patients per FTE, 75% DSCSA inquiry deflection, 138bp opex leverage improvement. Track whether these gains compound or plateau.
• Drug pricing reform: IRA Part D changes went live Jan 2026. Monitor MFN, Globe, and other legislative proposals. Management says navigable but political risk is non-zero.
• Capital return: ~$2B/year buyback program reducing shares 3-4% annually. Monitor pace and any changes to allocation priorities.

For the full analysis, see the Business Model, Financials, and Valuation pages.

Concerns, Catalysts & Risks -- full analysis

Buy at current levels -- McKesson is a high-quality compounder in a textbook oligopoly with multiple secular growth vectors and a management team that has raised guidance every quarter for three consecutive fiscal years. At $883.34 (near ATH), the stock trades at ~22.6x FY2026E earnings and ~20.1x FY2027E earnings. The premium to historical distribution multiples (~18-20x) is justified by the earnings growth trajectory but leaves moderate room for error.

The setup for FY2027 (ending March 2027) is strong. GLP-1 distribution provides a secular tailwind with years of runway. The oncology platform is compounding at 24%+ organically. AI/automation is delivering measurable operating leverage. The Med-Surg IPO is a clear catalyst on the horizon. And the buyback machine mechanically accretes 3-4% to EPS annually. The Leerink FY2027 EPS estimate of $44.04 implies continued 13-15% growth, which would compress the forward P/E to ~20x -- attractive for a company of this quality.

Risk management: The main risks are elevated valuation (any growth miss compresses the multiple), drug pricing reform overhang, and GLP-1 concentration risk. A pullback to the $750-$800 range (~18-20x FY2027E) on policy headlines or macro weakness would offer a more compelling entry. For existing holders, the fundamental trajectory supports continued ownership. For new positions, the quality and growth profile justify a full-sized entry with the understanding that the premium multiple requires sustained execution.